<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2207200116
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LORBRENA 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LORLATINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        7554.097
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Deutschland GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Deutschland GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lorbena is a prescription medicine &nbsp;used to treat adults with non-small cell lung cancer (NSCLC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene, <strong>and</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that has spread to other parts of your body ,</p><p>Your healthcare provider will perform a test to make sure that LORBRENA is right for you.</p><p>It is not known if LORBRENA is safe and effective in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Lorbrena:</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to lorlatinib or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you take certain other medicines called strong CYP3A inducers. Ask your healthcare provider for a list of these medicines if you are not sure.&nbsp; &nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p><strong>&nbsp;</strong></p><p>Before taking Lorbrena talk to your healthcare provider about all of your medical conditions, including , if you :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had episodes of depression or seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have high levels of cholesterol or triglycerides in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have problems with your heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have lung or breathing problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have diabetes or high blood sugar</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Lorbrena for a condition for which it was not prescribed. Do not give Lorbrena to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about Lorbrena that is written for health professionals.</p><p><strong>&nbsp;</strong></p><p><strong>Children&nbsp; and adolescents </strong></p><p><strong>&nbsp;</strong></p><p>It is not known if Lorbrena is safe and effective in children.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and&nbsp; Lorbrena&nbsp; </strong></p><p>&nbsp;</p><p>&nbsp;Tell your doctor or pharmacist if you are&nbsp; taking/using, have recently taken/used or might take use any other medicines.&nbsp;</p><p>&nbsp;</p><p>LORBRENA may affect the way other medicines work and other medicines may affect the way LORBRENA works causing side effects.</p><p>&nbsp;</p><p>Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility&nbsp; </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your&nbsp; doctor or pharmacist&nbsp;&nbsp; for advice before taking this medicine.&nbsp;</p><p>&nbsp;</p><p>Lorbrena can harm your unborn baby.</p><p>o&nbsp;&nbsp; Your healthcare provider will do a pregnancy test before you start treatment with Lorbrena.</p><p>o &nbsp;&nbsp;&nbsp;Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Lorbrena.</p><p>─&nbsp;&nbsp;&nbsp;&nbsp; <strong>Females</strong> who are able to become pregnant should use effective non-hormonal birth control during treatment with Lorbrena and for at least 6 months after the final dose of LORBRENA. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with Lorbrena. Talk to your healthcare provider about birth control choices that are right for you during this time.</p><p>─&nbsp;&nbsp;&nbsp;&nbsp; <strong>Males</strong> who have female partners who are able to become pregnant should use effective birth control during treatment with Lorbrena and for at least 3 months after the final dose of Lorbrena.</p><p>If you are breastfeeding or plan to breastfeed. It is not known if Lorbrena passes into your breast milk. Do not breastfeed during treatment with Lorbrena and for 7 days after the final dose. Talk to your healthcare provider about the best way to feed your baby during this time.<strong> </strong></p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p><strong>&nbsp;</strong></p><p>You should take special care when driving and using machines when taking Lorbrena because of its effects on your mental state.</p><p>&nbsp;</p><p><strong>Lorbrena contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p><strong>Lorbrena contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 25&nbsp;mg or 100&nbsp;mg tablet, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Take Lorbrena exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking Lorbrena unless your healthcare provider tells you to.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swallow Lorbrena tablets whole. Do not chew, crush, or split Lorbrena tablets. Do not take Lorbrena tablets if they are broken, cracked, or not intact.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Take Lorbrena 1 time a day, at the same time each day.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You may take Lorbrena with or without food.</p><p>&nbsp;</p><p><strong>If you vomit after taking a dose of Lorbrena</strong></p><p>&nbsp;</p><p>Do not take an extra dose. Take your next dose at your regular time.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;If you take more Lorbrena than you should&nbsp; </strong></p><p><strong>&nbsp;</strong></p><p>If you accidentally take too many tablets, tell your doctor or pharmacist right away. You may require medical attention</p><p><em>&nbsp;</em></p><p><strong>&nbsp;If you forget to take Lorbrena&nbsp; </strong></p><p>If you miss a dose, take it as soon as you remember. However, if it is close to the time of your next dose (within 4&nbsp;hours), just take your next dose at your regular time. <strong>Do not</strong> take 2 doses of LORBRENA at the same time to make up for the missed dose.</p><p>&nbsp;</p><p><strong>If you stop taking Lorbrena&nbsp; </strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;If you have any further questions on the use of this medicine, ask your&nbsp; doctor, or pharmacist or nurse.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Lorbrena may cause serious side effects, including:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liver problems due to interactions with other medicines.</strong> It is important to know what medicines should not be taken with Lorbrena.</p><p>o&nbsp;&nbsp; <strong>Central nervous system (CNS) </strong>effects. LORBRENA may cause CNS effects, including:</p><p>o&nbsp;&nbsp; &nbsp;problems with thinking ,such as forgetfulness or confusion</p><p>o&nbsp;&nbsp; Changes in mood such as depressionand thoughts about suicide or dying</p><p>o&nbsp;&nbsp; Psycholic effects, such as seeing or hearing things that are not real (hallucinations)</p><p>o&nbsp;&nbsp; &nbsp;seizures</p><p>o&nbsp;&nbsp; Changes in speech</p><p>o&nbsp;&nbsp; Changes in sleep</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Tell your healthcare provider if you experience new or worsening symptoms of these CNS effects during treatment with LORBRENA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Increases in the cholesterol and triglycerides (lipid) levels in your blood.</strong> Most people will have an increase in the lipid levels in their blood during treatment with Lorbrena.</p><p>o If you have increases in the lipid levels in your blood during treatment with Lorbrena, your healthcare provider may need to start you on a medicine to lower the levels. If you are already taking a medicine to lower the lipid levels in your blood, your healthcare provider may need to increase your dose of that medicine.</p><p>o Your healthcare provider should do blood tests to check the lipid levels in your blood before starting treatment, 1&nbsp;to 2 months after starting treatment, and during treatment with Lorbrena.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart problems.</strong> Lorbrena may cause very slow or abnormal heartbeats. Your healthcare provider should check your heart rhythm (electrocardiogram orEKG) before starting and during treatment with Lorbrena. Tell your healthcare provider right away if you feel dizzy or faint or have abnormal heartbeats. In some people, these problems are severe and your healthcare provider may need to have you stop taking Lorbrena or have a pacemaker placed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lung problems.</strong> Lorbrena may cause severe or life-threatening swelling (inflammation) of the lungs during treatment that can lead to death. Symptoms may be similar to those from lung cancer. Tell your healthcare provider right away if you have any new or worsening symptoms of lung problems, including trouble breathing, shortness of breath, cough, or fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>High blood pressure (hypertension).</strong> Your healthcare provider should check your blood pressure before starting treatment, 2 weeks after starting treatment, and then at least every month during treatment with LORBRENA. Your healthcare provider may need to start or change your blood pressure medicine if you have high blood pressure during treatment with LORBRENA. Tell your healthcare provider right away if you get signs or symptoms of high blood pressure, including: headaches, dizziness, blurred vision, chest pain or shortness of breath.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>High blood sugar (hyperglycemia). </strong>LORBRENA may increase your blood sugar levels. Your healthcare provider should do blood tests to check your blood sugar levels before starting and during treatment with LORBRENA. Your healthcare provider may need to start or change your blood sugar medicine to control your blood sugar levels. Tell your healthcare provider right away if you get new or worsening signs and symptoms of high blood sugar, including: &nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very thirsty</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; needing to urinate more than usual</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very hungry</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick to your stomach</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak or tired</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>If you have serious effects during treatment with LORBRENA, your healthcare provider may change your dose, stop Your treatment for a period of time or completely stop treatment with LORBRENA.</p><p>&nbsp;</p><p><strong>The most common side effects of Lorbrena include:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in your arms, legs, hands and feet (edema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness and tingling feeling in your joints or arms and legs (peripheral neuropathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with thinking, such as forgetfulness or confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in mood, such as depression and irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high cholesterol and triglyceride levels in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>Lorbrena may cause decreased fertility in males. In males, this could affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.</p><p>These are not all of the possible side effects of Lorbrena. For more information, ask your healthcare provider or pharmacist.</p><p>&nbsp;</p><p><strong>Reporting side effects : &nbsp;&nbsp;</strong></p><p>If you get any side effects, talk to your doctor, pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to National Pharmacovigilance Center (NPC). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>To Report any side effects :</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Saudi Arabia</strong></p><p><strong>National Pharmacovigilance Center ( NPC )</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center :19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Other GCC States</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp; Keep this medicine out of the reach and sight of children&nbsp;</p><p>&nbsp;</p><p>Store LORBRENA below 30&deg;C.</p><p>Do not use Lorbrena after the expiry date which is stated on Bottle / Blister. The expiry date refers to the last day of that month.&nbsp;</p><p>&nbsp;</p><p>Do not use this medicine if you notice that the package is damaged or shows signs of tampering.</p><p>&nbsp;</p><p>&nbsp;Do not throw away any medicines via wastewater&nbsp; or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Active ingredient: </strong>lorlatinib</p><p><strong>Inactive ingredients:</strong> microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate.</p><p>Film‑coating contains: hydroxypropyl methylcellulose (HPMC) 2910/hypromellose, lactose monohydrate, macrogol/ polyethylene glycol (PEG) 3350, triacetin, titanium dioxide, ferrosoferric oxide/black iron oxide, and iron oxide red.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Lorbrena 25 mg is supplied as round light pink film coated tablets, debossed with “Pfizer” on one side and “25” and “LLN” on the other side.
Lorbrena 25 mg is provided in bottles of 30 tablets.

Lorbrena 100 mg is supplied as oval dark pink film coated tablets, debossed with “Pfizer” on one side and “LLN 100” on the other side.
Lorbrena 100 mg is provided in bottles of 30 tablets.
	
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>&nbsp;</p><p>Pfizer Inc., USA</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p><strong>&nbsp;</strong></p><p>Pfizer Manufacturing Deutschland GmbH</p><p>Betriebsstatte, Freiburg, Germany</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;Packed and Released by:&nbsp; </strong></p><p>&nbsp;</p><p>Pfizer Pharmaceuticals LLC</p><p>KM 1.9 Road 689, Vega Baja, Puerto Rico</p><p>(PR) 00617, USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">لوربرينا هو دواء يُصرف بوصفة طبية يُستخدم لعلاج البالغين المصابين بسرطان الرئة غير صغير الخلايا (NSCLC)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذي يسببه جين كيناز سرطان الغدد الليمفاوية غير متمايز الخلايا (ALK) غير الطبيعي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>و</strong>انتشر إلى أجزاء أخرى من جسمهم،</p><p dir="RTL">سيجري مقدم الرعاية الصحية الخاص بك اختبارًا للتأكد من أن لوربرينا مناسب لك.</p><p dir="RTL">من غير المعروف إذا ما كان لوربرينا آمنًا وفعالًا للأطفال.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال لوربرينا:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه {لورلاتينيب} أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى أدوية معينة أخرى تسمى محفزات السيتوكروم CYP٣A القوية. اطلب من مُقدم الرعاية الصحية الخاص بك قائمة بهذه الأدوية إذا لم تكن متأكدًا.&nbsp; &nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال لوربرينا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل تناول لوربرينا، تحدث مع مُقدم الرعاية الصحية الخاص بك بشأن جميع الحالات الطبية التي تعاني منها، بما في ذلك إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات بالكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد أصبت بنوبات اكتئاب أو نوبات تشنجية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من ارتفاع مستويات الكوليسترول أو ثلاثيات الجليسريد في دمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في نبض قلبك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات بالرئتين أو التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من ضغط الدم المرتفع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من داء السكري أو ارتفاع مستوى سكر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; في بعض الأحيان توصف الأدوية لأغراض غير تلك المُدرجة في نشرة معلومات المريض. لا تستخدم لوربرينا لعلاج حالة لم يوصف لها. لا تعط لوربرينا إلى أشخاص آخرين، حتى إذا كانوا يعانون من نفس الأعراض التي تعاني منها. فقد يسبب لهم ضررًا. يمكنك أن تطلب من مُقدم الرعاية الصحية الخاص بك أو الصيدلي المزيد من المعلومات الخاصة بلوربرينا الموجّهة لمتخصصي الرعاية الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ليس معروفًا إذا ما كان لوربرينا آمنًا وفعالًا في الأطفال أم لا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;أخبر طبيبك أو الصيدلي إذا كنت تتناول/تستخدم أو تناولت/استخدمت مؤخرًا أو قد تتناول/تستخدم أي أدوية أخرى.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤثر لوربرينا على طريقة عمل الأدوية الأخرى وقد تؤثر الأدوية الأخرى على طريقة عمل لوربرينا، مما يسبب آثارًا جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اعرف الأدوية التي تتناولها. احتفظ بقائمة بها لعرضها على مقدم الرعاية الصحية الخاص بك والصيدلي عندما تحصل على دواء جديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يُلحق لوربرينا الضرر بجنينكِ.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يقوم مُقدم الرعاية الصحية الخاص بكِ بإجراء اختبار حمل قبل بدء علاجكِ بلوربرينا.</p><p dir="RTL">o&nbsp; &nbsp;&nbsp;&nbsp;أخبري مُقدم الرعاية الصحية الخاص بكِ على الفور إذا أصبحتِ حاملًا أو كنتِ تعتقدين أنكِ ربما تكونين حاملًا أثناء العلاج بلوربرينا.</p><p dir="RTL">─&nbsp;&nbsp;&nbsp;&nbsp; ينبغي <strong>للسيدات</strong> القادرات على الإنجاب أن يستخدمن وسيلة منع حمل فعالة غير هرمونية أثناء العلاج بلوربرينا ولمدة ٦ أشهر على الأقل بعد تلقي آخر جرعة من لوربرينا. يمكن ألا تكون حبوب منع الحمل (وسائل منع الحمل التي تؤخذ عن طريق الفم) والأشكال الهرمونية الأخرى من وسائل منع الحمل فعالة إذا تم استخدامها أثناء العلاج بلوربرينا. تحدثي إلى مُقدم الرعاية الصحية الخاص بكِ بخصوص خيارات منع الحمل المناسبة لكِ أثناء هذه الفترة.</p><p dir="RTL">─&nbsp;&nbsp;&nbsp;&nbsp; ينبغي <strong>للرجال</strong> الذين لديهم زوجات قادرات على الإنجاب أن يستخدموا وسيلة فعالة لمنع الحمل أثناء العلاج بلوربرينا ولمدة ٣ أشهر على الأقل بعد تلقي آخر جرعة من لوربرينا.</p><p dir="RTL">إذا كنتِ تُرضعين رضاعة طبيعية أو تخططين لذلك. فليس معروفًا إذا ما كان لوربرينا يمر إلى لبن الثدي لديكِ أم لا. لا تُرضعي رضاعة طبيعية أثناء العلاج بلوربرينا ولمدة ٧ أيام بعد تلقي آخر جرعة منه. تحدثي إلى مُقدم الرعاية الصحية الخاص بكِ بشأن أفضل طريقة لإطعام طفلكِ خلال ذلك الوقت.<strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير لوربرينا على القيادة واستخدام الآلات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ينبغي توخي الحذر بشكل خاص عند القيادة واستخدام الآلات أثناء استخدامك لوربرينا بسبب تأثيره على حالتك العقلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات لوربرينا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي لوربرينا على اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك أنك لا تستطيع تحمل بعض السكريات، فتواصل معه قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي لوربرينا على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ مليمول من الصوديوم (٢٣ ملجم) لكل قرص ٢٥ ملجم أو١٠٠ ملجم؛ لذا يُعد &quot;خاليًا من الصوديوم&quot; تقريبًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تناول لوربرينا تمامًا مثلما يخبرك مُقدم الرعاية الصحية الخاص بك. لا تغير جرعتك أو تتوقف عن تناول لوربرينا إلا إذا أخبرك مُقدم الرعاية الصحية الخاص بك بذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ابتلع أقراص لوربرينا كاملة. لا تمضغ أقراص لوربرينا، أو تسحقها، أو تقسمها. لا تتناول أقراص لوربرينا إذا كانت مكسورة، أو مشقوقة، أو إذا كانت غير سليمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تناول لوربرينا مرة واحدة يوميًا، في الوقت نفسه من كل يوم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; يمكنك تناول لوربرينا مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تقيأت بعد تناول جرعة من لوربرينا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">فلا تتناول جرعة إضافية. تناول جرعتك التالية في موعدها المُحدد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة الزائدة من لوربرينا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولت عددًا مفرطًا من الأقراص عن طريق الخطأ، فأخبر طبيبك أو الصيدلي على الفور. قد تتطلب حالتك عناية طبية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة لوربرينا</strong></p><p dir="RTL">إذا فاتتك إحدى الجرعات، فتناولها بمجرد تذكرها. ومع ذلك، إذا تذكرتها قرب موعد جرعتك التالية (خلال ٤ ساعات)، فتناول فقط جرعتك التالية في موعدها المُعتاد. <strong>لا</strong> تتناول جرعتين من لوربرينا في نفس الوقت لتعويض الجرعة الفائتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول لوربرينا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاطرحها على طبيبك أو الصيدلي أو الممرضة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على غرار جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يمكن أن يسبب لوربرينا آثارًا جانبية خطيرة، بما في ذلك:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشكلات بالكبد بسبب التفاعلات مع أدوية أخرى.</strong> من المهم معرفة الأدوية التي ينبغي عدم تناولها مع لوربرينا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; آثار<strong> </strong>على<strong> الجهاز العصبي المركزي </strong>(<strong>CNS</strong>)<strong>.</strong> قد يسبب لوربرينا آثارًا على الجهاز العصبي المركزي، بما في ذلك:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات بالتفكير، مثل النسيان أو الارتباك</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الحالة المزاجية، مثل الاكتئاب وأفكار حول الانتحار أو الموت</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار ذهانية، مثل رؤية أو سماع أشياء غير حقيقية (هلاوس)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الكلام</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في النوم</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أخبر مقدم الرعاية الصحية الخاص بك إذا أُصبت بأعراض جديدة أو متفاقمة خاصة بهذه الآثار على الجهاز العصبي المركزي أثناء العلاج بلوربرينا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>زيادة في مستويات الكوليسترول وثلاثيات الجليسريد (الدهون) في الدم.</strong> يعاني أغلب الأشخاص من ارتفاع في مستويات الدهون في دمهم أثناء العلاج بلوربرينا.</p><p dir="RTL">o&nbsp; إذا كنت تعاني من زيادات في مستويات الدهون في دمك أثناء العلاج بلوربرينا، فقد يحتاج مُقدم الرعاية الصحية الخاص بك إلى أن يعطيك دواء لخفض مستوياتها. إذا كنت تتناول بالفعل دواءً لخفض مستويات الدهون في دمك، فقد يحتاج مُقدم الرعاية الصحية الخاص بك إلى زيادة جرعتك من هذا الدواء.</p><p dir="RTL">o&nbsp; ينبغي أن يجري مُقدم الرعاية الصحية الخاص بك فحوصات دم للتحقق من مستويات الدهون في دمك قبل بدء العلاج، وبعد شهر إلى شهرين من بدء العلاج، وأثناء العلاج بلوربرينا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشكلات بالقلب.</strong> يمكن أن يسبب لوربرينا البطء الشديد لضربات القلب أو اضطرابها. ينبغي أن يفحص مُقدم الرعاية الصحية الخاص بك نظم القلب لديك (مخطط كهربية القلب أو EKG) قبل بدء العلاج بلوربرينا وأثنائه. أخبر مُقدم الرعاية الصحية الخاص بك على الفور إذا شعرت بالدوار أو أصبت بالإغماء أو إذا كانت ضربات قلبك غير طبيعية. في بعض الأشخاص، تكون هذه المشكلات شديدة ويمكن أن يطلب منك مُقدم الرعاية الصحية الخاص بك التوقف عن تناول لوربرينا أو وضع منظم ضربات قلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشكلات بالرئتين.</strong> يمكن أن يسبب لوربرينا تورمًا (التهابًا) شديدًا أو مهددًا للحياة بالرئتين أثناء العلاج، مما قد يؤدي إلى الوفاة. قد تكون الأعراض مشابهة لأعراض سرطان الرئة. أخبر مُقدم الرعاية الصحية الخاص بك على الفور إذا أصبت بأي أعراض جديدة أو متفاقمة لمشكلات الرئتين بما في ذلك صعوبة التنفس، أو ضيق التنفس، أو السعال، أو الحمى.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ضغط الدم المرتفع (ارتفاع ضغط الدم). </strong>ينبغي أن يقوم مقدم الرعاية الصحية الخاص بك بالتحقق من ضغط الدم لديك قبل بدء العلاج، وبعد بدء العلاج بأسبوعين، وبعد ذلك كل شهر على الأقل أثناء العلاج بلوربرينا. قد يحتاج مقدم الرعاية الصحية الخاص بك إلى البدء في وصف دواء ضغط الدم الخاص بك أو تغييره إذا كنت تعاني من ضغط الدم المرتفع أثناء العلاج بلوربرينا. أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا أصبت بعلامات أو أعراض ضغط الدم المرتفع، بما في ذلك: الصداع، أو الدوار، أو تغيم الرؤية، أو ألم الصدر، أو ضيق التنفس.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ارتفاع مستوى سكر الدم (فرط سكر الدم). </strong>قد يزيد لوربرينا من مستويات سكر الدم لديك. ينبغي أن يقوم مقدم الرعاية الصحية الخاص بك بإجراء اختبارات للدم للتحقق من مستويات سكر الدم لديك قبل بدء العلاج بلوربرينا وأثنائه. قد يحتاج مقدم الرعاية الصحية الخاص بك إلى البدء في وصف دواء سكر الدم الخاص بك أو تغييره للتحكم في مستويات سكر الدم لديك. أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا أصبت بعلامات وأعراض جديدة أو متفاقمة لارتفاع مستوى سكر الدم، بما في ذلك:</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الشعور بالعطش الشديد</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الحاجة إلى التبول أكثر من المعتاد</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الشعور بالجوع الشديد</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الشعور بالغثيان</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الشعور بالضعف أو التعب</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الشعور بالارتباك</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بآثار خطيرة أثناء العلاج بلوربرينا، يمكن أن يغير مُقدم الرعاية الصحية الخاص بك جرعتك، أو يوقف علاجك لفترة من الوقت أو يوقف العلاج بلوربرينا تمامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الآثار الجانبية الأكثر شيوعًا للوربرينا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم ذراعيك، وساقيك، ويديك، وقدميك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالخدر والتنميل في مفاصلك أو ذراعيك وساقيك (اعتلال الأعصاب الطرفية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التفكير، مثل النسيان أو الارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب (الإرهاق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في المزاج، مثل الاكتئاب والتهيج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات الكوليسترول وثلاثيات الجليسريد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">يمكن أن يسبب لوربرينا انخفاض معدل الخصوبة لدى الرجال. وفي الرجال، يمكن أن يؤثر هذا على قدرتهم على إنجاب طفل. تحدث إلى مقدم الرعاية الصحية الخاص بك إذا كانت لديك مخاوف بشأن الخصوبة.</p><p dir="RTL">لا تقتصر جميع الآثار الجانبية المحتملة للوربرينا على هذه الآثار فقط. لمزيد من المعلومات، اسأل مقدم الرعاية الصحية الخاص بك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية: &nbsp;&nbsp;</strong></p><p dir="RTL"><strong>إذا تعرضت لأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً في المركز الوطني للتيقظ والسلامة الدوائية. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن أي آثار جانبية:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المملكة العربية السعودية</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ والسلامة الدوائية </strong></p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>مركز الاتصال: ١٩٩٩٩</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دول الخليج الأخرى:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحفظ في درجة حرارة أقل من ۳٠ درجة مئوية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp; احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تستخدم لوربرينا بعد مرور تاريخ انتهاء الصلاحية المُدون على العبوة يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.&nbsp; </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أن العبوة تالفة أو تظهر عليها علامات عبث.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المكون الفعال: </strong>لورلاتينيب</p><p dir="RTL"><strong>المكونات غير الفعالة:</strong> السيليولوز البلوري المكروي، وفوسفات الكالسيوم ثنائي القاعدية اللا مائي، وجليكولات نشا الصوديوم، وستيارات المغنيسيوم.</p><p dir="RTL">تحتوي الطبقة المغلِفة الرقيقة على: هيدروكسي بروبيل ميثيل سيليولوز (HPMC) 2910/هيبروميلوز، ولاكتوز أحادي الهيدرات، وماكروجول/بولي إيثيلين جليكول (PEG) 3350، وثلاثي الأسيتين، وثاني أكسيد التيتانيوم، وأكسيد حديدوز الحديديك/أكسيد الحديد الأسود، وأكسيد الحديد الأحمر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يتوفر لوربرينا 25 ملجم في شكل أقراص دائرية بلون وردي فاتح مغلفة بطبقة رقيقة، مطبوع على أحد جانبيها كلمة &quot;Pfizer&quot; وعلى الجانب الآخر &quot;25&quot; و&quot;LLN&quot;.</strong></p><p dir="RTL"><strong>يتوفر لوربرينا 25 ملجم في عبوات تحتوي على 30 قرص.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يتوفر لوربرينا 100 ملجم في شكل أقراص بيضوية بلون وردي غامق مغلفة بطبقة رقيقة، مطبوع على أحد جانبيها كلمة &quot;Pfizer&quot; و&quot;LLN&nbsp;100&quot; على الجانب الآخر.</strong></p><p dir="RTL"><strong>يتوفر لوربرينا 100 ملجم في عبوات تحتوي على 30 قرص.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>Pfizer Inc., USA</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة:</strong></p><p dir="RTL"><strong>Pfizer Manufacturing Deutschland GmbHBetriebsstatte, Freiburg, Germany</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شركة التغليف والفسح النهائي:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>Pfizer Pharmaceuticals LLC</strong></p><p dir="RTL"><strong>KM 1.9 Road 689, Vega Baja, Puerto Rico </strong></p><p dir="RTL"><strong>00</strong> <strong>617</strong> PR <strong>, USA</strong></p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lorbrena 25 mg film coated tablets
Lorbrena 100 mg film coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lorbrena 25 mg film coated tablets

Each film coated tablet contains 25 mg of lorlatinib.

Excipient with known effect
Each film coated tablet contains 1.58 mg of lactose monohydrate.

Lorbrena 100 mg film coated tablets

Each film coated tablet contains 100 mg of lorlatinib.

Excipient with known effect 
Each film coated tablet contains 4.20 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet.

Lorbrena 25 mg film coated tablets

Round (8 mm) light pink immediate release film coated tablet, debossed with “Pfizer” on one side and “25” and “LLN” on the other side.

Lorbrena 100 mg film coated tablets

Oval (8.5 × 17 mm) dark pink immediate release film coated tablet, debossed with “Pfizer” on one side and “LLN 100” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LORBRENA<sup>&reg;</sup> is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose &nbsp;tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA approved test</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Patient Selection </strong></p><p><strong>&nbsp;</strong></p><p>Select patients for the treatment of metastatic NSCLC with LORBRENA based on the presence of ALK positivity in tumor specimens <em>[see 4.1 Therapeutic indications and 5.1 Pharmacodynamic properties]</em>.</p><p>&nbsp;</p><p><strong>Recommended Dosage</strong></p><p>&nbsp;</p><p>The recommended dosage of LORBRENA is 100&nbsp;mg orally once daily, with or without food, until disease progression or unacceptable toxicity<em> [see 5.2 Pharmacokinetic properties]</em>.</p><p>&nbsp;</p><p>Swallow tablets whole. Do not chew, crush or split tablets. Do not ingest if tablets are broken, cracked, or otherwise not intact.</p><p>&nbsp;</p><p>Take LORBRENA at the same time each day. If a dose is missed, then take the missed dose unless the next dose is due within 4&nbsp;hours. Do not take 2&nbsp;doses at the same time to make up for a missed dose.</p><p>&nbsp;</p><p>Do not take an additional dose if vomiting occurs after LORBRENA but continue with the next scheduled dose.</p><p>&nbsp;</p><p><strong>Dosage Modifications for Adverse Reactions </strong></p><p>&nbsp;</p><p>The recommended dose reductions are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First dose reduction: LORBRENA 75&nbsp;mg orally once daily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second dose reduction: LORBRENA 50&nbsp;mg orally once daily</p><p>&nbsp;</p><p>Permanently discontinue LORBRENA in patients who are unable to tolerate 50&nbsp;mg orally once daily.</p><p>&nbsp;</p><p>Dosage modifications for adverse reactions of LORBRENA are provided in Table&nbsp;1.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;1</strong><strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended LORBRENA Dosage Modifications for Adverse Reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse Reaction<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Dosage Modifications</strong></p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Central Nervous System Effects</strong><em> [see 4.4 Special warnings and precautions for use]</em></p></td></tr><tr><td><p>Grade&nbsp;1</p></td><td><p>Continue at the same dose or withhold the dose until recovery to baseline. Resume LORBRENA at the same dose or at a reduced dose.</p></td></tr><tr><td><p>Grade&nbsp;2 <u>OR </u>Grade&nbsp;3</p></td><td><p>Withhold dose until Grade&nbsp;0 or 1. Resume LORBRENA at a reduced dose.</p></td></tr><tr><td><p>Grade&nbsp;4</p></td><td><p>Permanently discontinue LORBRENA.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hyperlipidemia</strong><em> [see 4.4 Special warnings and precautions for use]</em></p></td></tr><tr><td><p>Grade 4 hypercholesterolemia <u>OR</u></p><p>Grade 4 hypertriglyceridemia</p></td><td><p>Withhold LORBRENA until recovery of hypercholesterolemia and/or hypertriglyceridemia to less than or equal to Grade 2. Resume LORBRENA at the same dose.</p><p>&nbsp;</p><p>If severe hypercholesterolemia and/or hypertriglyceridemia recurs, resume LORBRENA at a reduced dose.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Atrioventricular (AV) Block</strong><em> [see 4.4 Special warnings and precautions for use]</em></p></td></tr><tr><td><p>Second-degree AV block</p></td><td><p>Withhold LORBRENA until PR interval is less than 200&nbsp;ms. Resume LORBRENA at a reduced dose.</p></td></tr><tr><td><p>First occurrence of complete AV block</p></td><td><p>Withhold LORBRENA until</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pacemaker placed <u>OR</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PR interval less than 200&nbsp;ms.</p><p>&nbsp;</p><p>If a pacemaker is placed, resume LORBRENA at the same dose.</p><p>&nbsp;</p><p>If no pacemaker is placed, resume LORBRENA at a reduced dose.</p></td></tr><tr><td><p>Recurrent complete AV block</p></td><td><p>Place pacemaker or permanently discontinue LORBRENA.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Interstitial Lung Disease (ILD)/Pneumonitis </strong><em>[see 4.4 Special warnings and precautions for use]</em></p></td></tr><tr><td><p>Any Grade treatment&ndash;related ILD/Pneumonitis</p></td><td><p>Permanently discontinue LORBRENA.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Other Adverse Reactions</strong></p></td></tr><tr><td colspan="2"><p><strong>Hypertension</strong> <em>[see 4.4 Special Warnings and Precautions for use]</em></p></td></tr><tr><td><p>Grade 3 (SBP greater than or equal to 160 mmHg or DBP greater than or equal to 100 mmHg; medical intervention indicated; more than one antihypertensive drug, or more intensive therapy than previously used indicated)</p></td><td><p>Withhold LORBRENA until hypertension has recovered to Grade 1 or less (SBP less than 140 mmHg and DBP less than 90 mmHg), then resume LORBRENA at the same dose.</p><p>&nbsp;</p><p>If Grade 3 hypertension recurs, withhold LORBRENA until recovery to Grade 1 or less, and resume at a reduced dose.</p><p>&nbsp;</p><p>If adequate hypertension control cannot be achieved with optimal medical management, permanently discontinue LORBRENA.</p></td></tr><tr><td><p>Grade 4 (life-threatening consequences, urgent intervention indicated)</p></td><td><p>Withhold LORBRENA until recovery to Grade 1 or less, and resume at a reduced dose or permanently discontinue LORBRENA.</p><p>&nbsp;</p><p>If Grade 4 hypertension recurs, permanently discontinue LORBRENA.</p></td></tr><tr><td colspan="2"><p><strong>Hyperglycemia</strong> <em>[see 4.4 Special Warnings and Precautions for use]</em> &nbsp;</p></td></tr><tr><td><p>Grade 3 ((greater than 250 mg/dL) despite optimal anti-hyperglycemic therapy <u>OR</u> Grade 4</p></td><td><p>Withhold LORBRENA until hyperglycemia is adequately controlled, then resume LORBRENA at the next lower dosage.</p><p>&nbsp;</p><p>If adequate hyperglycemic control cannot be achieved with optimal medical management, permanently discontinue LORBRENA.</p></td></tr><tr><td><p>Grade&nbsp;1 <u>OR</u> Grade&nbsp;2</p></td><td><p>Continue LORBRENA at same dose or reduced dose.</p></td></tr><tr><td><p>Grade&nbsp;3 <u>OR</u> Grade 4</p></td><td><p>Withhold LORBRENA until symptoms resolve to less than or equal to Grade&nbsp;2 or baseline. Resume LORBRENA at reduced dose.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Abbreviation: AV=atrioventricular; DBP=diastolic blood pressure; SBP=systolic blood pressure.</p><p><sup>a</sup> Grade based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Concomitant Use of Strong CYP3A Inducers</strong></p><p>&nbsp;</p><p>LORBRENA is contraindicated in patients taking strong CYP3A inducers. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA. &nbsp;<em>[see 4.3 Contraindications, 4.4 Special warnings and precautions for use, 4.5 Interaction with other medicinal products and other forms of interaction,5.2 Pharmacokinetic properties].</em></p><p><em>&nbsp;</em></p><p><strong>Concomitant Use of Moderate CYP3A Inducers</strong></p><p><strong>&nbsp;</strong></p><p>Avoid concomitant use of moderate CYP3A inducers with LORBRENA. If concomitant use with moderate CYP3A inducers is unavoidable, increase the LORBRENA dose to 125 mg once daily <em>[see 4.5 Interaction with other medicinal products and other forms of interaction, 5.2 Pharmacokinetic properties]</em>.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><strong>Dosage Modification for Strong CYP3A Inhibitors</strong></p><p>&nbsp;</p><p>Avoid concomitant use of LORBRENA with strong CYP3A inhibitors. If concomitant use with a strong CYP3A inhibitor is unavoidable, reduce the starting dose of LORBRENA from 100&nbsp;mg orally once daily to 75&nbsp;mg orally once daily.</p><p>&nbsp;</p><p>In patients who have had a dose reduction to 75 mg orally once daily due to adverse reactions and who initiate a strong CYP3A inhibitor, reduce the LORBRENA dose to 50 mg orally once daily.</p><p>&nbsp;</p><p>If concomitant use of a strong CYP3A inhibitor is discontinued, increase the LORBRENA dose (after 3 plasma half-lives of the strong CYP3A inhibitor) to the dose that was used before starting the strong inhibitor <em>[see </em><em>4.5 Interaction with other medicinal products and other forms of interaction</em><em> ,5.2 Pharmacokinetic properties]</em>.</p><p>&nbsp;</p><p><strong>Dosage Modification for Fluconazole</strong></p><p>&nbsp;</p><p>Avoid concomitant use of LORBRENA with fluconazole <em>[see Clinical Pharmacology (12.3)]</em>. If concomitant use is unavoidable, reduce the starting dose of LORBRENA from 100&nbsp;mg orally once daily to 75&nbsp;mg orally once daily <em>[see 4.5 Interaction with other medicinal products and other forms of interaction, 5.2 Pharmacokinetic properties]</em>.</p><p>&nbsp;</p><p><strong>Dosage Modification for Severe Renal Impairment </strong></p><p>&nbsp;</p><p>Reduce the recommended dosage of LORBRENA for patients with severe renal impairment (creatinine clearance [CL<sub>cr</sub>] 15 to &lt; 30 mL/min, estimated by Cockcroft‑Gault) from 100 mg to 75 mg orally once daily <em>[see 4.4 Special warnings and precautions for use and 5.2 Pharmacokinetic &nbsp;properties]</em>.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity [see 4.4 Special warnings and precautions for use].
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Risk of Serious Hepatotoxicity with Concomitant Use of Strong CYP3A Inducers </strong></p><p>&nbsp;</p><p>Severe hepatotoxicity occurred in 10 of 12 healthy subjects receiving a single dose of LORBRENA with multiple daily doses of rifampin, a strong CYP3A inducer. Grade 4 alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations occurred in 50% of subjects, Grade 3 ALT or AST elevations occurred in 33% and Grade 2 ALT or AST elevations occurred in 8%. ALT or AST elevations occurred within 3 days and returned to within normal limits after a median of 15 days (7 to 34 days); the median time to recovery was 18&nbsp;days in subjects with Grade 3 or 4 ALT or AST elevations and 7 days in subjects with Grade 2 ALT or AST elevations <em>[see </em><em>4.5 Interaction with other medicinal products and other forms of interaction</em><em>]</em>.</p><p>&nbsp;</p><p>LORBRENA is contraindicated<em> </em>in patients taking strong CYP3A inducers. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA <em>[see </em><em>4.3 Contraindications, 4.5 Interaction with other medicinal products and other forms of interaction</em><em>]</em>.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Central Nervous System Effects</strong></p><p>&nbsp;</p><p>A broad spectrum of central nervous system (CNS) effects can occur in patients receiving LORBRENA. These include seizures, psychotic effects and changes in cognitive function, mood (including suicidal ideation), speech, mental status, and sleep. Overall, CNS effects occurred in 52% of &nbsp;the 476 patients who received 100 mg LORBRENA once daily in clinical trials <em>[see 4.8 undesirable effects]</em>. Cognitive effects occurred in 28% of the 476 patients; 2.9% of these events were severe (Grade 3 or 4). Mood effects occurred in 21% of patients; 1.7% of these events were severe. Speech effects occurred in 11% of patients; 0.6% of these events were severe. Psychotic effects occurred in 7% of patients; 0.6% of these events were severe. Mental status changes occurred in 1.3% of patients; 1.1% of these events were severe. Seizures occurred in 1.9% of patients, sometimes in conjunction with other neurologic findings. Sleep effects occurred in 12% of patients. The median time to first onset of any CNS effect was 1.4 months (1 day to 3.4 years). Overall, 2.1% of patients required permanent discontinuation of LORBRENA for a CNS effect; 10% required temporary discontinuation and 8% required dose reduction.</p><p>&nbsp;</p><p>Withhold and resume at the same dose or at a reduced dose or permanently discontinue LORBRENA based on severity <em>[see 4.2 Posology and methods of administration]</em>.</p><p>&nbsp;</p><p><strong>Hyperlipidemia</strong></p><p>&nbsp;</p><p>Increases in serum cholesterol and triglycerides can occur in patients receiving LORBRENA <em>[see 4.8 undesirable effects]</em>. Grade 3 or 4 elevations in total cholesterol occurred in 18% and Grade 3 or 4 elevations in triglycerides occurred in 19% of the 476 patients who received 100 mg LORBRENAonce daily. The median time to onset was 15 days for both hypercholesterolemia and hypertriglyceridemia. Approximately 4% and 7% of patients required temporary discontinuation and 1% and 3% of patients required dose reduction of LORBRENA for elevations in cholesterol and in triglycerides. in Study B7461001 and Study B7461006, respectively. Eighty-three percent of patients required initiation of lipid-lowering medications, with a median time to onset of start of such medications of 17 &nbsp;days.</p><p>&nbsp;</p><p>Initiate or increase the dose of lipid-lowering agents in patients with hyperlipidemia. Monitor serum cholesterol and triglycerides before initiating LORBRENA, 1 and 2 months after initiating LORBRENA, and periodically thereafter. Withhold and resume at the same dose for the first occurrence; resume at the same or a reduced dose of LORBRENA for recurrence based on severity <em>[see 4.2 Posology and methods of administration].</em>&nbsp;</p><p>&nbsp;</p><p><strong>Atrioventricular Block</strong></p><p>&nbsp;</p><p>PR interval prolongation and atrioventricular (AV) block can occur in patients receiving LORBRENA <em>[see 4.8 undesirable effects, 5.1 Pharmacodynamic properties].</em> In 476 patients who received 100 mg LORBRENA once daily and who had a baseline electrocardiography (ECG), 1.9% experienced AV&nbsp;block and 0.2% experienced Grade 3 AV block and underwent pacemaker placement.</p><p>&nbsp;</p><p>Monitor ECG prior to initiating LORBRENA and periodically thereafter. Withhold and resume at a reduced dose or at the same dose in patients who undergo pacemaker placement. Permanently discontinue for recurrence in patients without a pacemaker <em>[see 4.2 Posology and methods of administration]</em>.</p><p>&nbsp;</p><p><strong>Interstitial Lung Disease/Pneumonitis</strong></p><p>&nbsp;</p><p>Severe or life-threatening pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis can occur with LORBRENA. ILD/pneumonitis occurred in 1.9% of patients who received 100 mg LORBRENAonce daily, including Grade 3 or 4 ILD/pneumonitis in 0.6% of patients. Four patients (0.8%) discontinued LORBRENA for ILD/pneumonitis.</p><p>&nbsp;</p><p>Promptly investigate for ILD/pneumonitis in any patient who presents with worsening of respiratory symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, and fever). Immediately withhold LORBRENA in patients with suspected ILD/pneumonitis. Permanently discontinue LORBRENA for treatment-related ILD/pneumonitis of any severity <em>[see 4.2 Posology and methods of administration]</em>.</p><p>&nbsp;</p><p><strong>Hypertension</strong></p><p>&nbsp;</p><p>Hypertension can occur in patients receiving LORBRENA <em>[see 4.8 Undesirable effects]</em>. Hypertension occurred in 13% of patients who received 100 mg LORBRENA once daily, including Grade 3 or 4 in 6% of patients. The median time to onset of hypertension was 6.4&nbsp;months (1 day to 2.8 years), and 2.3% of patients temporarily discontinued LORBRENA for hypertension.</p><p>&nbsp;</p><p>Control blood pressure prior to initiation of LORBRENA. Monitor blood pressure after 2 weeks and at least monthly thereafter during treatment with LORBRENA. Withhold and resume at a reduced dose or permanently discontinue LORBRENA based on severity <em>[see 4.2 Posology and method of administration]</em>.</p><p>&nbsp;</p><p><strong>Hyperglycemia</strong></p><p>&nbsp;</p><p>Hyperglycemia can occur in patients receiving LORBRENA <em>[see 4.8 Undesirable effects]</em>. Hyperglycemia occurred in 9% of patients who received 100 mg LORBRENA, including Grade 3 or 4 in 3.2% of patients. The median time to onset of hyperglycemia was 4.8 months (1 day to 2.9 years), and 0.8% of patients temporarily discontinued LORBRENA for hyperglycemia.</p><p>&nbsp;</p><p>Assess fasting serum glucose prior to initiation of LORBRENA and monitor periodically thereafter. Withhold and resume at a reduced dose or permanently discontinue LORBRENA based on severity <em>[see 4.2 Posology and method of administration]</em>.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Embryo‑Fetal Toxicity</strong></p><p>&nbsp;</p><p>Based on findings from animal studies and its mechanism of action, LORBRENA can cause fetal harm when administered to a pregnant woman. Administration of lorlatinib to pregnant rats and rabbits by oral gavage during the period of organogenesis resulted in malformations, increased post-implantation loss, and abortion at maternal exposures that were equal to or less than the human exposure at the recommended dose of 100 mg once daily based on area under the curve (AUC).</p><p>&nbsp;</p><p>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with LORBRENA and for 3 months after the final dose <em>[see 4.5 Interaction with other medicinal products and other forms of interaction, 4.6 Fertility, pregnancy and lactation, 5.3 Preclinical safety data]</em>.</p><p>&nbsp;</p><p><strong>Pediatric Use</strong></p><p>&nbsp;</p><p>The safety and effectiveness of LORBRENA in pediatric patients have not been established.</p><p>&nbsp;</p><p><strong>Geriatric Use</strong></p><p>&nbsp;</p><p>Of the &nbsp;patients in Study B7461001 (N=295) and Study B7461006 (N=149) who received 100 mg LORBRENA orally once daily, 18% and 40% of patients, respectively, were aged 65&nbsp;years or older. No clinically important differences in safety or efficacy were observed between patients aged 65&nbsp;years or older and younger patients.</p><p>&nbsp;</p><p><strong>Hepatic Impairment</strong></p><p>&nbsp;</p><p>No dose adjustment is recommended for patients with mild hepatic impairment (total bilirubin &le; upper limit of normal [ULN] with AST &gt; ULN or total bilirubin &gt;1 to 1.5 &times; ULN with any AST). The recommended dose of LORBRENA has not been established for patients with moderate (total bilirubin &ge; 1.5 to 3.0 &times; ULN with any AST) or severe (total bilirubin &gt; 3.0 &times; ULN with any AST) hepatic impairment <em>[see 5.2 Pharmacokinetic properties]</em>.</p><p>&nbsp;</p><p><strong>Renal</strong><strong> Impairment</strong></p><p>&nbsp;</p><p>Reduce the dose when administering LORBRENA to patients with severe (CL<sub>cr</sub> 15 to &lt;30 mL/min, estimated by Cockcroft Gault) renal impairment <em>[see 4.2 Posology and method of administration and 5.2 Pharmacokinetic properties]</em>.</p><p>&nbsp;</p><p>No dose adjustment is recommended for patients with mild or moderate (CL<sub>cr</sub> 30 to 89&nbsp; mL/min estimated by Cockcroft-Gault) renal impairment <em>[see 5.2 Pharmacokinetic properties]</em>.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effect of Other Drugs on LORBRENA</strong></p><p><u>&nbsp;</u></p><p><u>Strong CYP3A Inducers </u></p><p>Concomitant use of LORBRENA with a strong CYP3A inducer decreased lorlatinib plasma concentrations <em>[see 5.2 Pharmacokinetic properties]</em>, which may decrease the efficacy of LORBRENA.</p><p>&nbsp;</p><p>Severe hepatotoxicity occurred in healthy subjects receiving LORBRENA with rifampin, a strong CYP3A inducer. In 12 healthy subjects receiving a single 100 mg dose of LORBRENA with multiple daily doses of rifampin, Grade 3 or 4 increases in ALT or AST occurred in 83% of subjects and Grade 2 increases in ALT or AST occurred in 8%. A possible mechanism for hepatotoxicity is through activation of the pregnane X receptor (PXR) by LORBRENA and rifampin, which are both PXR agonists.</p><p>LORBRENA is contraindicated in patients taking strong CYP3A inducers <em>[see 4.3 Contraindication]</em>. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA <em>[ see 4.2 Posology and method of administration].</em></p><p>&nbsp;</p><p><u>Moderate CYP3A Inducers</u></p><p>Concomitant use of LORBRENA with a moderate CYP3A inducer decreased lorlatinib plasma concentrations, which may decrease the efficacy of LORBRENA <em>[see 5.2 Pharmacokinetic properties]</em>. Avoid concomitant use of moderate CYP3A inducers with LORBRENA. If concomitant use is unavoidable, increase the LORBRENA dose <em>[see 4.2 Posology and method of administration]</em>.</p><p>&nbsp;</p><p><u>Strong CYP3A Inhibitors</u></p><p>Concomitant use with a strong CYP3A inhibitor increased lorlatinib plasma concentrations<em> see 5.2 Pharmacokinetic properties] </em>which may increase the incidence and severity of adverse reactions of LORBRENA. Avoid the concomitant use of LORBRENA with a strong CYP3A inhibitor. If concomitant use cannot be avoided, reduce the LORBRENA dosage<em>[see 4.2 Posology and method of administration, 5.2Pharmacokinetic properties]</em>.</p><p>&nbsp;</p><p><u>Fluconazole</u></p><p>Concomitant use of LORBRENA with fluconazole may increase lorlatinib plasma concentrations <em>[see 5.2 Pharmacokinetic properties]</em>, which may increase the incidence and severity of adverse reactions of LORBRENA. Avoid concomitant use of LORBRENA with fluconazole. If concomitant use cannot be avoided, reduce the LORBRENA dosage <em>[see 4.2 Posology and method of administration]</em>.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Effect of LORBRENA on Other Drugs</strong></p><p>&nbsp;</p><p><u>Certain CYP3A Substrates</u></p><p>LORBRENA is a moderate CYP3A inducer. Concomitant use of LORBRENA decreases the concentration of CYP3A substrates <em>[see</em> <em>5.2 Pharmacokinetic properties]</em>, which may reduce the efficacy of these substrates. Avoid concomitant use of LORBRENA with certain CYP3A substrates, for which minimal concentration changes may lead to serious therapeutic failures. If concomitant use is unavoidable, increase the CYP3A substrate dosage in accordance with approved product labeling.</p><p>&nbsp;</p><p><u>Certain P-glycoprotein (P-gp) Substrates</u></p><p>LORBRENA is a moderate P-gp inducer. Concomitant use of LORBRENA decreases the concentration of P-gp substrates <em>[see 5.2 Pharmacokinetic properties], </em>which may reduce the efficacy of these substrates. Avoid concomitant use of LORBRENA with certain P-gp substrates for which minimal concentration changes may lead to serious therapeutic failures. If concomitant use is unavoidable, increase the P-gp substrate dosage in accordance with approved product labeling.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p><strong>&nbsp;</strong></p><p><u>Risk Summary</u></p><p><u>&nbsp;</u></p><p>Based on findings from animal studies and its mechanism of action <em>[see 5.1 Pharmacodynamic properties]</em>, LORBRENA can cause embryo‑fetal harm when administered to a pregnant woman. There are no available data on LORBRENA use in pregnant women. Administration of lorlatinib to pregnant rats and rabbits by oral gavage during the period of organogenesis resulted in malformations, increased post-implantation loss, and abortion at maternal exposures that were equal to or less than the human exposure at the recommended dose of 100 mg once daily based on AUC<em> (see Data)</em>. Advise a pregnant woman of the potential risk to a fetus.</p><p>&nbsp;</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.</p><p>&nbsp;</p><p><u>Data</u></p><p><u>&nbsp;</u></p><p><em>Animal Data</em></p><p>Preliminary embryo-fetal development studies investigating the administration of lorlatinib during the period of organogenesis were conducted in rats and rabbits. In rabbits, lorlatinib administration resulted in abortion and total loss of pregnancy at doses of 15 mg/kg (approximately 3 times the human exposure at the recommended dose of 100 mg) or greater. At a dose of 4 mg/kg (approximately 0.6 times the human exposure at the recommended dose of 100 mg) toxicities included increased post-implantation loss and malformations including rotated limbs, malformed kidneys, domed head, high arched palate, and dilation of the cerebral ventricles. In rats, administration of lorlatinib resulted in total loss of pregnancy at doses of 4 mg/kg (approximately 5 times the human exposure at the recommended dose of 100 mg) or greater. At a dose of 1 mg/kg (approximately equal to the human exposure at the recommended dose of 100 mg) there was increased post-implantation loss, decreased fetal body weight, and malformations including gastroschisis, rotated limbs, supernumerary digits, and vessel abnormalities.</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p><strong>&nbsp;</strong></p><p><u>Risk Summary</u></p><p>There are no data on the presence of lorlatinib or its metabolites in either human or animal milk or its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in breastfed infants, instruct women not to breastfeed during treatment with LORBRENA and for 7 days after the final dose.</p><p><strong>&nbsp;</strong></p><p><strong>Females and Males of Reproductive Potential</strong></p><p>&nbsp;</p><p><u>Pregnancy Testing</u></p><p>Verify pregnancy status in females of reproductive potential prior to initiating LORBRENA <em>.</em></p><p>&nbsp;</p><p><u>Contraception </u></p><p>LORBRENA can cause embryo‑fetal harm when administered to a pregnant woman <em>.</em></p><p>&nbsp;</p><p><em>Females </em></p><p>Advise female patients of reproductive potential to use effective non-hormonal contraception during treatment with LORBRENA and for at least 6 months after the final dose. Advise females of reproductive potential to use a non‑hormonal method of contraception, because LORBRENA can render hormonal contraceptives ineffective <em>[see 4.5 Interaction with other medicinal products and other forms of interaction]</em>.</p><p>&nbsp;</p><p><em>Males </em></p><p>Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with LORBRENA and for at least 3 months after the final dose <em>[see 5.3 Preclinical safety data]</em>.</p><p>&nbsp;</p><p><u>Infertility</u></p><p><u>&nbsp;</u></p><p><em>Males</em></p><p>Based on findings from animal studies, LORBRENA may transiently impair male fertility <em>[see 5.3 Preclinical safety data]</em>.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lorlatinib has moderate influence on the ability to drive and use machines. Caution should be exercised when driving or operating machines as patients may experience CNS effects (see Section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>The following adverse reactions are described elsewhere in the labeling:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk of Serious Hepatotoxicity with Concomitant Use of Strong CYP3A Inducers <em>[see 4.4 Special warnings and precautions for use]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Central Nervous System Effects <em>[see 4.4 Special warnings and precautions for use]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperlipidemia <em>[see 4.4 Special warnings and precautions for use]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atrioventricular Block <em>[see 4.4 Special warnings and precautions for use]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interstitial Lung Disease/Pneumonitis <em>[see 4.4 Special warnings and precautions for use]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension <em>[see 4.4 Special Warnings and Precautions for use]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperglycemia <em>[see 4.4 Special Warnings and Precautions for use]</em></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Clinical Trials Experience</strong></p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p>&nbsp;</p><p>The pooled safety population described in the Warnings and Precautions section reflects exposure to LORBRENA in 476 patients who received 100 mg LORBRENA once daily in Study B7461001 (N=327) and Study B7461006 (N=149). Among 476 patients who received LORBRENA, 75% were exposed for 6 months or longer and 61% were exposed for greater than 1 year. In this pooled safety population, the most frequent adverse reactions in &ge; 20% of 476 patients who received LORBRENA were edema (56%), peripheral neuropathy (44%), weight gain (31%), cognitive effects (28%), fatigue (27%), dyspnea (27%), arthralgia (24%), diarrhea (23%), mood effects (21%), and cough (21%). The most frequent Grade 3-4 laboratory abnormalities in &ge; 20% of 476 patients who received LORBRENA were hypercholesterolemia (21%) and hypertriglyceridemia (21%).</p><p>&nbsp;</p><p><u>Previously Untreated </u><u>ALK-Positive Metastatic NSCLC (CROWN Study)</u></p><p>&nbsp;</p><p>The safety of LORBRENA was evaluated in 149 patients with ALK-positive NSCLC in a randomized, open‑label, active-controlled trial for the treatment of patients with ALK-positive, locally advanced or metastatic, NSCLC who had not received previous systemic treatment for advanced disease <em>[see 5.1 Pharmacodynamic properties].</em> The median duration of exposure to LORBRENA was 16.7&nbsp;months (4 days to 34.3&nbsp;months) and 76% received LORBRENA for at least 12&nbsp;months.</p><p>&nbsp;</p><p>Serious adverse reactions occurred in 34% of patients treated with LORBRENA; the most frequently reported serious adverse reactions were pneumonia (4.7%), dyspnea (2.7%), respiratory failure (2.7%), cognitive effects (2.0%), and pyrexia (2.0%). Fatal adverse reactions occurred in 3.4% of patients treated with LORBRENA and included pneumonia (0.7%), respiratory failure (0.7%), cardiac failure acute (0.7%), pulmonary embolism (0.7%), and sudden death (0.7%).</p><p>&nbsp;</p><p>Permanent discontinuation of LORBRENA due to adverse reactions occurred in 6.7% of patients. The most frequent adverse reaction that led to permanent discontinuation of LORBRENA was cognitive effects (1.3%). Adverse reactions leading to dose interruptions occurred in 49% of patients treated with LORBRENA. The most frequent adverse reactions that led to dose interruptions of LORBRENA were hypertriglyceridemia (7%), edema (5%), pneumonia (4.7%) cognitive effects (4.0%), mood effects (4.0%), and hypercholesterolemia (3.4%). Adverse reactions leading to dose reductions occurred in 21% of patients treated with LORBRENA. The most frequent adverse reactions that led to dose reductions were edema (5%), hypertriglyceridemia (4.0%), and peripheral neuropathy (3.4%).</p><p>&nbsp;</p><p>Tables 2 and 3 summarize most frequent adverse reactions and laboratory abnormalities, respectively, in patients treated with LORBRENA in Study B7461006.</p><p>&nbsp;</p><p><strong>Table 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions (</strong><strong>&ge;</strong><strong>10% for all NCI CTCAE Grades or &ge;2% for Grades 3-4) in Patients Treated with LORBRENA in Study B7461006*</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>LORBRENA</strong></p><p><strong>N=149</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Crizotinib</strong></p><p><strong>N=142</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p>Psychiatric</p><p>Mood effects<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system</p><p>Peripheral neuropathy<sup>b</sup></p><p>Cognitive effects<sup>c </sup></p><p>Headache</p><p>Dizziness</p><p>Sleep effects<sup>d</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>34</p><p>21</p><p>17</p><p>11</p><p>11</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2</p><p>2</p><p>0</p><p>0</p><p>1.3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>15</p><p>6</p><p>18</p><p>14</p><p>10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.7</p><p>0</p><p>0.7</p><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory</p><p>Dyspnea</p><p>Cough</p><p>Respiratory failure</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>20</p><p>16</p><p>2.7</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.7</p><p>0</p><p>2</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16</p><p>18</p><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.1</p><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p><p>Hypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>18</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.1</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Ocular</p><p>Vision disorder<sup>e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>18</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>39</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p><p>Diarrhea</p><p>Nausea</p><p>Constipation</p><p>Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>21</p><p>15</p><p>17</p><p>13</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.3</p><p>0.7</p><p>0</p><p>0.7</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>52</p><p>52</p><p>30</p><p>39</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.7</p><p>2.1</p><p>0.7</p><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue</p><p>Arthralgia</p><p>Myalgia<sup>f</sup></p><p>Back pain</p><p>Pain in extremity</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19</p><p>15</p><p>15</p><p>17</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.7</p><p>0.7</p><p>0.7</p><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11</p><p>7</p><p>11</p><p>8</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0</p><p>0</p><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>General</p><p>Edema<sup>g</sup></p><p>Weight gain</p><p>Fatigue<sup>h</sup></p><p>Pyrexia</p><p>Chest pain</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>56</p><p>38</p><p>19</p><p>17</p><p>11</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4</p><p>17</p><p>1.3</p><p>1.3</p><p>1.3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>40</p><p>13</p><p>32</p><p>13</p><p>14</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.4</p><p>2.1</p><p>2.8</p><p>1.4</p><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Infections</p><p>Upper respiratory tract infection<sup>i</sup></p><p>Pneumonia</p><p>Bronchitis</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11</p><p>7.4</p><p>6.7</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.7</p><p>2</p><p>2</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.7</p><p>8.5</p><p>2.1</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.4</p><p>3.5</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Skin</p><p>Rash<sup>j</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.5</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*&nbsp; Adverse reactions were graded using NCI CTCAE version 4.03.</p><p>Abbreviations: NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; SOC=System organ class.</p><p><sup>a</sup>&nbsp; Mood effects (including affective disorder, affect lability, agitation, anger, anxiety, bipolar I disorder, depressed mood, depression, depressive symptom, euphoric mood, intentional self-injury, irritability, mood altered, mood swings, stress).</p><p><sup>b</sup>&nbsp; Peripheral neuropathy (including dysesthesia, gait disturbance, hypoesthesia, motor dysfunction, muscular weakness, neuralgia, neuropathy peripheral, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy).</p><p><sup>c</sup>&nbsp; Cognitive effects (including events from SOC Nervous system disorders: amnesia, cognitive disorder, disturbance in attention, memory impairment, mental impairment; and also including events from SOC Psychiatric disorders: confusional state, delirium, disorientation).</p><p><sup>d</sup>&nbsp; Sleep effects (including insomnia, nightmare, sleep disorder, somnambulism).</p><p><sup>e&nbsp;&nbsp;&nbsp; </sup>Vision disorder (including diplopia, photophobia, photopsia, vision blurred, visual acuity reduced, visual impairment, vitreous floaters).</p><p><sup>f</sup>&nbsp; Myalgia (including musculoskeletal pain, myalgia).</p><p><sup>g</sup>&nbsp; Edema (including edema, edema peripheral, eyelid edema, face edema, generalized edema, localized edema, periorbital edema, peripheral swelling, swelling).</p><p><sup>h&nbsp;&nbsp; </sup>Fatigue (including asthenia, fatigue).</p><p><sup>i&nbsp;&nbsp;&nbsp; </sup>Upper respiratory tract infection (including upper respiratory infection).</p><p><sup>j</sup><sup>&nbsp;&nbsp;&nbsp; </sup>Rash (including dermatitis acneiform, maculopapular rash, rash).</p></td></tr></tbody></table><p>&nbsp;</p><p>Additional clinically significant adverse reactions occurring at an incidence between 1% and 10% were speech effects (6.7%) and psychotic effects (3.4%).</p><p>&nbsp;</p><p><strong>Table 3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laboratory Abnormalities Worsening from Baseline in <u>&gt;</u>20% of Patients in Study B7461006</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>Laboratory Abnormality</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>LORBRENA</strong></p><p><strong>N=149</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Crizotinib</strong></p><p><strong>N=142</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Chemistry</p><p>Hypertriglyceridemia<sup>a,A</sup></p><p>Hypercholesterolemia<sup>a,A</sup></p><p>Increased creatinine<sup>a,A</sup></p><p>Increased GGT<sup>a,A</sup></p><p>Increased AST<sup>a,A</sup></p><p>Hyperglycemia<sup>a,A</sup></p><p>Increased ALT<sup>a,A</sup></p><p>Increased CPK<sup>a,A</sup></p><p>Hypoalbuminemia<sup>a,A</sup></p><p>Increased lipase<sup>a,A</sup></p><p>Increased alkaline phosphatase<sup>a,A</sup></p><p>Hyperkalemia<sup>a,A</sup></p><p>Increased amylase<sup>b,A</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>95</p><p>91</p><p>81</p><p>52</p><p>48</p><p>48</p><p>44</p><p>39</p><p>36</p><p>28</p><p>23</p><p>21</p><p>20</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>22</p><p>19</p><p>0.7</p><p>6</p><p>2</p><p>7</p><p>2.7</p><p>2</p><p>0.7</p><p>7</p><p>0</p><p>1.3</p><p>1.4</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>27</p><p>12</p><p>99</p><p>41</p><p>75</p><p>27</p><p>75</p><p>64</p><p>61</p><p>34</p><p>50</p><p>27</p><p>32</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0</p><p>0</p><p>2.1</p><p>6</p><p>3.5</p><p>2.1</p><p>4.3</p><p>5</p><p>6</p><p>5</p><p>0.7</p><p>2.1</p><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Hematology</p><p>Anemia<sup>a,A</sup></p><p>Activated PTT<sup>c,B</sup></p><p>Lymphopenia<sup>a,A</sup></p><p>Thrombocytopenia<sup>a,A</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>48</p><p>25</p><p>23</p><p>23</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2</p><p>0</p><p>2.7</p><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>38</p><p>14</p><p>43</p><p>7</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.8</p><p>0</p><p>6</p><p>0.7</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*&nbsp; Grades using NCI CTCAE version 4.03.</p><p>Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; GGT=gamma glutamyl transferase; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; PTT=partial&nbsp;thromboplastin time.</p><p>N=number of patients who had at least one on‑study assessment for the parameter of interest.</p><p><sup>a&nbsp;&nbsp;&nbsp; </sup>N=149 (LORBRENA).</p><p><sup>A&nbsp;&nbsp; </sup>N=141 (crizotinib).</p><p><sup>b</sup>&nbsp; N=148 (LORBRENA).</p><p><sup>B</sup>&nbsp; N=135 (crizotinib).</p><p><sup>c</sup>&nbsp;&nbsp; N=138 (LORBRENA).</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Previously Treated ALK-Positive Metastatic NSCLC </u></p><p>&nbsp;</p><p>&nbsp;</p><p>The data described below reflect exposure to LORBRENA in 295 patients with ALK‑positive or ROS1‑positive metastatic NSCLC who received LORBRENA 100&nbsp;mg orally once daily in Study B7461001, a multi-cohort, non‑comparative trial <em>[see 5.1 Pharmacological properties]</em>. The median duration of exposure to LORBRENA was 12.5&nbsp;months (1&nbsp;day to 35&nbsp;months) and 52% received LORBRENA for &ge;12&nbsp;months. Patient characteristics were a median age of 53&nbsp;years (19 to 85&nbsp;years), age &ge;65&nbsp;years (18%), female&nbsp;(58%), White (49%), Asian (37%), and ECOG performance status 0 or 1 (96%).</p><p>&nbsp;</p><p>The most frequent (&ge;20%) adverse reactions were edema, peripheral neuropathy, cognitive effects, dyspnea, fatigue, weight gain, arthralgia, mood effects, and diarrhea. Of the worsening laboratory values occurring in&nbsp; &ge;20% of patients, the most frequent &nbsp;were hypercholesterolemia, hypertriglyceridemia, anemia, hyperglycemia, increased AST, hypoalbuminemia, increased ALT, increased lipase, and increased alkaline phosphatase.</p><p>&nbsp;</p><p>Serious adverse reactions occurred in 32% of the 295 patients; the most frequently reported serious adverse reactions were pneumonia (3.4%), dyspnea (2.7%), pyrexia (2%), mental status changes (1.4%), and respiratory failure (1.4%). Fatal adverse reactions occurred in 2.7% of patients and included pneumonia (0.7%), myocardial infarction (0.7%), acute pulmonary edema (0.3%), embolism (0.3%), peripheral artery occlusion (0.3%), and respiratory distress (0.3%). Permanent discontinuation of LORBRENA for adverse reactions occurred in 8% of patients.</p><p>&nbsp;</p><p>The most frequent adverse reactions that led to permanent discontinuation were respiratory failure (1.4%), dyspnea (0.7%), myocardial infarction (0.7%), cognitive effects (0.7%) and mood effects (0.7%). Approximately 48% of patients required dose interruption. The most frequent adverse reactions that led to dose interruptions were edema (7%), hypertriglyceridemia (6%), peripheral neuropathy (5%), cognitive effects (4.4%), increased lipase (3.7%), hypercholesterolemia (3.4%), mood effects (3.1%), dyspnea (2.7%), pneumonia (2.7%), and hypertension (2.0%). Approximately 24% of patients required at least 1 dose reduction for adverse reactions. The most frequent adverse reactions that led to dose reductions were edema (6%), peripheral neuropathy (4.7%), cognitive effects (4.1%), and mood effects (3.1%).</p><p>&nbsp;</p><p>Tables 3 and 4 summarize most frequent adverse reactions and laboratory abnormalities, respectively, in patients treated with LORBRENA in Study B7461001.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3"><p><strong>Table 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Adverse Reactions Occurring in &ge;10% of Patients in Study </strong><strong>B7461001</strong><strong><sup>*</sup></strong><strong> </strong></p></td></tr><tr><td rowspan="2"><p><strong>Adverse Reaction</strong></p></td><td colspan="2"><p><strong>LORBRENA</strong></p><p><strong>(N=295)</strong></p></td></tr><tr><td><p><strong>All Grades</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p>Psychiatric</p><p>Mood effects<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>23</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.7</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system</p><p>Peripheral neuropathy<sup>b</sup></p><p>Cognitive effects<sup>c </sup></p><p>Headache</p><p>Dizziness</p><p>Speech effects<sup>d</sup></p><p>Sleep effects<sup>e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>47</p><p>27</p><p>18</p><p>16</p><p>12</p><p>10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.7</p><p>2</p><p>0.7</p><p>0.7</p><p>0.3</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory</p><p>Dyspnea</p><p>Cough</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>27</p><p>18</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Ocular</p><p>Vision disorder<sup>f</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>15</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p><p>Diarrhea</p><p>Nausea</p><p>Constipation</p><p>Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>22</p><p>18</p><p>15</p><p>12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.7</p><p>0.7</p><p>0</p><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue</p><p>Arthralgia</p><p>Myalgia<sup>g</sup></p><p>Back pain</p><p>Pain in extremity</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>23</p><p>17</p><p>13</p><p>13</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.7</p><p>0</p><p>0.7</p><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>General</p><p>Edema<sup>h</sup></p><p>Fatigue<sup>i</sup></p><p>Weight gain</p><p>Pyrexia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>57</p><p>26</p><p>24</p><p>12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3.1</p><p>0.3</p><p>4.4</p><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Infections</p><p>Upper respiratory tract infection<sup>j</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Skin</p><p>Rash<sup>k</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>14</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.3</p></td></tr></tbody></table><p>&nbsp;</p><p>*&nbsp; Adverse reactions were graded using NCI CTCAE version 4.03.</p><p>Abbreviations: NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; SOC=System organ class.</p><p><sup>a</sup>&nbsp; Mood effects (including affective disorder, affect lability, aggression, agitation, anxiety, depressed mood, depression, euphoric mood, irritability, mania, mood altered, mood swings, personality change, stress, suicidal ideation).</p><p><sup>b</sup>&nbsp; Peripheral neuropathy (including burning sensation, carpal tunnel syndrome, dysesthesia, formication, gait disturbance, hypoesthesia, muscular weakness, neuralgia, neuropathy peripheral, neurotoxicity, paresthesia, peripheral sensory neuropathy, sensory disturbance).</p><p><sup>c</sup>&nbsp; Cognitive effects (including events from SOC Nervous system disorders: amnesia, cognitive disorder, dementia, disturbance in attention, memory impairment, mental impairment; and also including events from SOC Psychiatric disorders: attention deficit/hyperactivity disorder, confusional state, delirium, disorientation, reading disorder).</p><p><sup>d</sup>&nbsp; Speech effects (including aphasia, dysarthria, slow speech, speech disorder)</p><p><sup>e</sup>&nbsp; Sleep effects (including abnormal dreams, insomnia, nightmare, sleep disorder, sleep talking, somnambulism)</p><p><sup>f&nbsp;&nbsp;&nbsp; </sup>Vision disorder (including blindness, diplopia, photophobia, photopsia, vision blurred, visual acuity reduced, visual impairment, vitreous floaters).</p><p><sup>g</sup>&nbsp; Myalgia (including musculoskeletal pain, myalgia).</p><p><sup>h</sup>&nbsp; Edema (including edema, edema peripheral, eyelid edema, face edema, generalized edema, localized edema, periorbital edema, peripheral swelling, swelling).</p><p><sup>i&nbsp;&nbsp;&nbsp; </sup>Fatigue (including asthenia, fatigue).</p><p><sup>j&nbsp;&nbsp;&nbsp; </sup>Upper respiratory infection (including fungal upper respiratory infection, upper respiratory infection, viral upper respiratory infection).</p><p><sup>k</sup>&nbsp; Rash (including dermatitis acneiform, maculopapular rash, pruritic rash, rash).</p><p>&nbsp;</p><p>Additional clinically significant adverse reactions occurring at an incidence between 1% and 10% were psychotic effects (7%).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3"><p><strong>Table 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening Laboratory Values Occurring in &ge;20% of Patients in Study B7461001* </strong></p></td></tr><tr><td rowspan="2"><p><strong>Laboratory Abnormality</strong></p></td><td colspan="2"><p><strong>LORBRENA</strong></p></td></tr><tr><td><p><strong>All Grades</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Grade 3 or 4</strong></p><p><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Chemistry</p><p>Hypercholesterolemia<sup>a</sup></p><p>Hypertriglyceridemia<sup>a</sup></p><p>Hyperglycemia<sup>b</sup></p><p>Increased AST<sup>a</sup></p><p>Hypoalbuminemia<sup>c</sup></p><p>Increased ALT<sup>a</sup></p><p>Increased lipase<sup>d</sup></p><p>Increased alkaline phosphatase<sup>a</sup></p><p>Increased amylase<sup>e</sup></p><p>Hypophosphatemia<sup>a</sup></p><p>Hyperkalemia<sup>b</sup></p><p>Hypomagnesemia<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>96</p><p>90</p><p>52</p><p>37</p><p>33</p><p>28</p><p>24</p><p>24</p><p>22</p><p>21</p><p>21</p><p>21</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>18</p><p>18</p><p>5</p><p>2.1</p><p>1</p><p>2.1</p><p>10</p><p>1</p><p>3.9</p><p>4.8</p><p>1</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hematology</p><p>Anemia<sup>b</sup></p><p>Thrombocytopenia<sup>b</sup></p><p>Lymphopenia<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>52</p><p>23</p><p>22</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.8</p><p>0.3</p><p>3.4</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp; Grades using NCI CTCAE version 4.03.</p><p>Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events.</p><p>N=number of patients who had at least one on‑study assessment for the parameter of interest.</p><p><sup>a&nbsp;&nbsp;&nbsp; </sup>N=292.</p><p><sup>b</sup>&nbsp; N=293.</p><p><sup>c</sup>&nbsp; N=291.</p><p><sup>d</sup>&nbsp; N=290.</p><p><sup>e</sup>&nbsp;&nbsp; N=284.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Reporting of adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p><u>&nbsp;</u></p><p><u>To report any side effects:</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Saudi Arabia</strong></p><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center :19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of overdose with the medicinal product consists of general supportive measures. Given the dose‑dependent effect on PR interval, ECG monitoring is recommended. There is no antidote for lorlatinib.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>LORBRENA (lorlatinib) is a kinase inhibitor for oral administration. The molecular formula is C21H19FN6O2 (anhydrous form) and the molecular weight is 406.41 Daltons. The chemical name is (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11] benzoxadiazacyclotetradecine-3-carbonitrile. The chemical structure is shown below:</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:137pt;
 height:100.5pt' o:ole="">
 <v:imagedata src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="183" height="134" src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="ChemDraw.Document.6.0" ShapeID="_x0000_i1025"
  DrawAspect="Content" ObjectID="_1690267178">
 </o:OLEObject>
</xml><![endif]--></p><p>&nbsp;</p><p>Lorlatinib is a white to off-white powder with a pKa of 4.92. The solubility of lorlatinib in aqueous media decreases over the range pH 2.55 to pH 8.02 from 32.38 mg/mL to 0.17 mg/mL. The log of the distribution coefficient (octanol/water) at pH 9 is 2.45.</p><p>&nbsp;</p><p><strong>Mechanism of Action</strong></p><p>&nbsp;</p><p>Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1 as well as TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK. Lorlatinib demonstrated in vitro activity against multiple mutant forms of the ALK enzyme, including some mutations detected in tumors at the time of disease progression on crizotinib and other ALK inhibitors.</p><p>&nbsp;</p><p>In mice subcutaneously implanted with tumors harboring EML4 fusions with either ALK variant 1 or ALK mutations, including the G1202R and I1171T mutations detected in tumors at the time of disease progression on ALK inhibitors, administration of lorlatinib resulted in antitumor activity. Lorlatinib also demonstrated anti‑tumor activity and prolonged survival in mice implanted intracranially with EML4‑ALK-driven tumor cell lines. The overall antitumor activity of lorlatinib in in vivo models was dose‑dependent and correlated with inhibition of ALK phosphorylation.</p><p>&nbsp;</p><p><strong>Pharmacodynamics</strong></p><p>&nbsp;</p><p>Exposure</p><p>-response relationships for Grade 3 or 4 hypercholesterolemia and for any Grade 3 or 4 adverse reaction were observed at steady-state exposures achieved at the recommended dosage, with higher probability of the occurrence of adverse reactions with increasing lorlatinib exposure.</p><p>&nbsp;</p><p><u>Cardiac Electrophysiology</u></p><p>In 295 patients who received LORBRENA at the recommended dosage of 100 mg once daily and had an ECG measurement in Study B7461001, the maximum mean change from baseline for PR interval was 16.4&nbsp;ms (2‑sided 90% upper confidence interval [CI] 19.4 ms). Among the 284 patients with PR interval &lt;200 ms at baseline, 14% had PR interval prolongation &ge;200&nbsp;ms after starting LORBRENA. The prolongation of PR interval occurred in a concentration-dependent manner. Atrioventricular block occurred in 1% of patients.</p><p>&nbsp;</p><p>In 275 patients who received LORBRENA at the recommended dosage in the activity-estimating portion of Study&nbsp;B7461001, no large mean increases from baseline in the QTcF interval (i.e., &gt;20 ms) were detected.</p><p>&nbsp;</p><p><strong>Clinical Studies </strong></p><p><strong>&nbsp;</strong></p><p><u>Previously Untreated ALK-Positive Metastatic NSCLC (CROWN Study)</u></p><p>&nbsp;</p><p>The efficacy of LORBRENA for the treatment of patients with ALK-positive NSCLC who had not received prior systemic therapy for metastatic disease was established in an open-label, randomized, active-controlled, multicenter study (Study&nbsp;B7461006; NCT03052608). Patients were required to have an ECOG performance status of 0-2 and ALK-positive NSCLC as identified by the VENTANA ALK (D5F3) CDx assay. Neurologically stable patients with treated or untreated asymptomatic CNS metastases, including leptomeningeal metastases, were eligible. Patients were required to have finished radiation therapy, at least 2&nbsp;weeks (for stereotactic or partial radiation) or 4 weeks (for whole brain irradiation) prior to randomization. Patients with severe acute or chronic psychiatric conditions, including recent (within the past year) or active suicidal ideation or behavior, were excluded.</p><p>&nbsp;</p><p>Patients were randomized 1:1 to receive LORBRENA 100 mg orally once daily or crizotinib 250 mg orally twice daily. Randomization was stratified by ethnic origin (Asian vs. non-Asian) and the presence or absence of CNS metastases at baseline. Treatment on both arms was continued until disease progression or unacceptable toxicity. The major efficacy outcome measure was progression-free survival (PFS) as determined by Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). Additional efficacy outcome measures were overall survival (OS) and tumor assessment related data by BICR, including overall response rate (ORR), and duration of response (DOR). In patients with measurable CNS metastases at baseline, additional outcome measures were intracranial overall response rate (IC-ORR) and intracranial duration of response (IC-DOR) by BICR.</p><p>&nbsp;</p><p>A total of 296 patients were randomized to LORBRENA (n=149) or crizotinib (n=147). The demographic characteristics of the overall study population were: median age 59 years (range: 26 to 90 years), age &ge;65&nbsp;years (35%), 59% female, 49% White, 44% Asian, and 0.3% Black. The ECOG performance status at baseline was 0 or 1 in 96% of patients. The majority of patients had adenocarcinoma (95%) and never smoked (59%). CNS metastases were present in 26% (n=78) of patients: of these, 30 patients had measurable CNS lesions.</p><p>&nbsp;</p><p>Efficacy results from Study&nbsp;B7461006 as assessed by BICR are summarized in Table 5 and Figure 1. Results demonstrated a significant improvement in PFS for the LORBRENA arm over the crizotinib arm. At the data cutoff point OS data was not mature.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2"><p><strong>Table&nbsp;5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy Results in Study B7461006 (CROWN)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Efficacy Parameter</strong></p></td><td><p><strong>LORBRENA</strong></p><p><strong>N=149</strong></p></td><td><p><strong>Crizotinib</strong></p><p><strong>N=147</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression‑free survival </strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events, n (%)</p></td><td style="vertical-align:top"><p>41 (28%)</p></td><td style="vertical-align:top"><p>86 (59%)</p></td></tr><tr><td style="vertical-align:top"><p>Progressive disease, n (%)</p></td><td style="vertical-align:top"><p>32 (22%)</p></td><td style="vertical-align:top"><p>82 (56%)</p></td></tr><tr><td style="vertical-align:top"><p>Death, n (%)</p></td><td style="vertical-align:top"><p>9 (6%)</p></td><td style="vertical-align:top"><p>4 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)<sup>a</sup></p></td><td style="vertical-align:top"><p>NE (NE, NE)</p></td><td style="vertical-align:top"><p>9.3 (7.6, 11.1)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.28 (0.19, 0.41)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>*</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall response rate </strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall response rate (95% CI)<sup>c</sup></p></td><td style="vertical-align:top"><p>76% (68, 83)</p></td><td style="vertical-align:top"><p>58% (49, 66)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>0%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>73%</p></td><td style="vertical-align:top"><p>58%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Duration of response </strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of responders, n</p></td><td style="vertical-align:top"><p>113</p></td><td style="vertical-align:top"><p>85</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (Range)</p></td><td style="vertical-align:top"><p>NE (0.9, 31.3)</p></td><td style="vertical-align:top"><p>11 (1.1, 27.5)</p></td></tr><tr><td style="vertical-align:top"><p>Response duration &ge;6 months, n (%)</p></td><td style="vertical-align:top"><p>101 (89%)</p></td><td style="vertical-align:top"><p>53 (62%)</p></td></tr><tr><td style="vertical-align:top"><p>Response duration &ge;12 months, n (%)</p></td><td style="vertical-align:top"><p>79 (70%)</p></td><td style="vertical-align:top"><p>23 (27%)</p></td></tr><tr><td style="vertical-align:top"><p>Response duration &ge;18 months, n (%)</p></td><td style="vertical-align:top"><p>34 (30%)</p></td><td style="vertical-align:top"><p>9 (11%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Abbreviations: CI=confidence interval; N=number of patients; NE=not estimable; PFS=progression free survival.</p><p><sup>*</sup>&nbsp; p-value based on 1-sided stratified log-rank test.</p><p><sup>a</sup>&nbsp; Based on the Brookmeyer and Crowley method.</p><p><sup>b</sup> Hazard ratio based on Cox proportional hazards model.</p><p><sup>c</sup>&nbsp; Using exact method based on binomial distribution.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure 1: Kaplan-Meier Plot of Progression-Free Survival by BICR in </strong><strong>Study&nbsp;B7461006 (</strong><strong>CROWN)</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_1" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:507.5pt;
 height:339.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="677" height="453" src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.jpg" /></p><p>&nbsp;</p><p>The results of prespecified exploratory analyses of intracranial response rate in 30 patients with measurable CNS lesions at baseline as assessed by BICR are summarized in Table 6.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3"><p><strong>Table&nbsp;6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intracranial Response Rate in Patients with Measurable Intracranial Lesions in CROWN</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Intracranial Tumor Response Assessment </strong>&nbsp;</p></td><td><p><strong>LORBRENA</strong></p><p><strong>N=17</strong></p></td><td><p><strong>Crizotinib</strong></p><p><strong>N=13</strong></p></td></tr><tr><td style="vertical-align:top"><p>Intracranial response rate (95% CI)<sup>a</sup><sub> </sub>&nbsp;</p></td><td style="vertical-align:top"><p>82% (57, 96)</p></td><td style="vertical-align:top"><p>23% (5, 54)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>71%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Duration of response &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of responders, n</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Response duration &ge;12 months, n (%)</p></td><td style="vertical-align:top"><p>11 (79%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Abbreviations: CI=confidence interval; N/n=number of patients.</p><p><sup>a</sup>&nbsp; Using exact method based on binomial distribution.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>ALK-Positive Metastatic NSCLC Previously Treated with an ALK Kinase Inhibitor </strong></p><p>&nbsp;</p><p>The efficacy of LORBRENA was demonstrated in a subgroup of patients with ALK-positive metastatic NSCLC previously treated with one or more ALK kinase inhibitors who were enrolled in a non‑randomized, dose-ranging and activity-estimating, multi‑cohort, multicenter study (Study&nbsp;B7461001; NCT01970865). Patients included in this subgroup were required to have metastatic disease with at least 1&nbsp;measurable target lesion according to RECIST version 1.1 (v1.1), ECOG performance status of 0 to 2, and documented ALK rearrangement in tumor tissue as determined by fluorescence in situ hybridization (FISH) assay or by Immunohistochemistry (IHC), and received LORBRENA 100 mg orally once daily. Patients with asymptomatic CNS metastases, including patients with stable or decreasing steroid use within 2 weeks prior to study entry, were eligible. Patients with severe, acute, or chronic psychiatric conditions including suicidal ideation or behavior were excluded. In addition, for patients with ALK-positive metastatic NSCLC, the extent and type of prior treatment was specified for each individual cohort (see Table 7). The major efficacy outcome measures were ORR and intracranial ORR, according to RECIST v1.1, as assessed by Independent Central Review (ICR) committee. Data were pooled across all subgroups listed in Table 4. Additional efficacy outcome measures included DOR, and intracranial DOR.</p><p>&nbsp;</p><p>A total of 215&nbsp;patients were enrolled across the subgroups in Table 7. The distribution of patients by type and extent of prior therapy is provided in Table 7. The demographic characteristics across all 215 patients were: 59%&nbsp;female, 51%&nbsp;White, 34%&nbsp;Asian, and the median age was 53&nbsp;years (29 to 85&nbsp;years) with 18% of patients &ge;65&nbsp;years. The ECOG performance status at baseline was 0 or 1 in 96%&nbsp;of patients. All patients had metastatic disease and 95% had adenocarcinoma. Brain metastases as identified by ICR were present in 69% of patients; of these, 60% had received prior radiation to the brain and 60% (n=89) had measurable disease per ICR.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extent of Prior Therapy in the Subgroup of Patients with Previously Treated ALK-Positive Metastatic NSCLC in Study B7461001</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Extent of prior therapy</strong></p></td><td style="vertical-align:top"><p><strong>Number of patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>Prior crizotinib and no prior chemotherapy<sup>a</sup></p></td><td style="vertical-align:top"><p>29</p></td></tr><tr><td style="vertical-align:top"><p>Prior crizotinib and 1-2 lines of prior chemotherapy<sup>a</sup></p></td><td style="vertical-align:top"><p>35</p></td></tr><tr><td style="vertical-align:top"><p>Prior ALK inhibitor (not crizotinib) with or without prior chemotherapy<sup>a</sup></p></td><td style="vertical-align:top"><p>28</p></td></tr><tr><td style="vertical-align:top"><p>Two prior ALK inhibitors with or without prior chemotherapy<sup>a</sup></p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>Three prior ALK inhibitors with or without prior chemotherapy<sup>a</sup></p></td><td style="vertical-align:top"><p>48</p></td></tr><tr><td style="vertical-align:top"><p>Total</p></td><td style="vertical-align:top"><p>215</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Abbreviations: ALK=anaplastic lymphoma kinase; NSCLC=non‑small cell lung cancer.</p><p><sup>a&nbsp;&nbsp; </sup>Chemotherapy administered in the metastatic setting.</p></td></tr></tbody></table><p>&nbsp;</p><p>Efficacy results for Study&nbsp;B7461001 are summarized in Tables&nbsp;8 and 9.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td colspan="2"><p><strong>Table&nbsp;8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy Results in Study B7461001</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Efficacy Parameter</strong></p></td><td><p><strong>Overall</strong></p><p><strong>N=215</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall response rate<sup>a</sup></strong> (95% CI)<sup>b</sup></p><p>Complete response</p><p>Partial response</p></td><td style="vertical-align:top"><p>48% (42, 55)</p><p>4%</p><p>44%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response</strong></p><p>Median, months<sup>c</sup> (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>12.5 (8.4, 23.7)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Abbreviations: CI=confidence interval; N=number of patients.</p><p><sup>a</sup>&nbsp; Per Independent Central Review.</p><p><sup>b</sup>&nbsp; Using exact method based on binomial distribution.</p><p><sup>c</sup>&nbsp; Estimated using the Kaplan Meier method.</p></td></tr></tbody></table><p>&nbsp;</p><p>An assessment of intracranial ORR and the duration of response for CNS metastases in the subgroup of 89&nbsp;patients in Study B7461001 with baseline measurable lesions in the CNS according to RECIST v1.1 are summarized in Table 9. Of these, 56 (63%) patients received prior brain radiation, including 42 patients (47%) who completed brain radiation treatment at least 6 months before starting treatment with LORBRENA.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td colspan="2"><p><strong>Table&nbsp;9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intracranial Response Rate in Patients with Measurable Intracranial Lesions in Study&nbsp;B7461001</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>Efficacy Parameter</strong></p></td><td><p><strong>Intracranial</strong></p><p><strong>N=89</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Intracranial response rate<sup>a</sup></strong> (95% CI)<sup>b</sup></p><p>Complete response</p><p>Partial response</p></td><td style="vertical-align:top"><p>60% (49, 70)</p><p>21%</p><p>38%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response</strong></p><p>Median, months<sup>c</sup> (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19.5 (12.4, NR)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Abbreviations: CI=confidence interval; N=number of patients; NR=not&nbsp;reached.</p><p><sup>a</sup>&nbsp; Per Independent Central Review.</p><p><sup>b</sup>&nbsp; Using exact method based on binomial distribution.</p><p><sup>c</sup>&nbsp; Estimated using the Kaplan‑Meier method.</p></td></tr></tbody></table><p>&nbsp;</p><p>In exploratory analyses conducted in subgroups defined by prior therapy, the response rates to LORBRENA were:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORR = 39% (95% CI: 30, 48) in 119 patients who received crizotinib and at least one other ALK inhibitor, with or without prior chemotherapy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORR = 31% (95% CI: 9, 61) in 13 patients who received alectinib as their only ALK inhibitor, with or without prior chemotherapy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORR = 46% (95% CI: 19, 75) in 13 patients who received ceritinib as their only ALK inhibitor, with or without prior chemotherapy</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Steady-state lorlatinib maximum plasma concentration (Cmax) increases proportionally and AUC increased slightly less than proportionally over the dose range of 10 mg to 200 mg orally once daily (0.1 to 2 times the recommended dosage). At the recommended dosage, the mean (coefficient of variation [CV] %) Cmax was 577 ng/mL (42%) and the AUC0-24h was 5650 ng·h/mL (39%) in patients with cancer. Lorlatinib oral clearance increased at steady-state compared to single dose, indicating autoinduction.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>The median lorlatinib Tmax was 1.2 hours (0.5 to 4 hours) following a single oral 100 mg dose and 2 hours (0.5 to 23 hours) following 100 mg orally once daily at steady state.</p><p>The mean absolute bioavailability is 81% (90% CI 75.7%, 86.2%) after oral administration compared to intravenous administration.</p><p>&nbsp;</p><p><em>Effect of Food</em></p><p>&nbsp;There was no clinically significant effect on lorlatinib pharmacokinetics following administrationof LORBRENA with a high fat, high calorie meal (approximately 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Lorlatinibwas 66% bound to plasma proteins at a concentration of 2.4 &micro;M. The blood-to-plasma ratio was 0.99, in vitro The mean (CV%) steady state volume of distribution (Vss) was 305 L (28%) following a single intravenous dose.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The mean plasma half life (t&frac12;) of lorlatinib was 24 hours (40%) after a single oral 100 mg dose of LORBRENA. The mean oral clearance (CL/F) was 11 L/h (35%) following a single oral 100 mg dose and increased to 18 L/h (39%) at steady state, suggesting autoinduction.</p><p>&nbsp;</p><p><em>Metabolism</em></p><p>Lorlatinib is metabolized primarily by CYP3A4 and UGT1A4, with minor contribution from CYP2C8, CYP2C19, CYP3A5, and UGT1A3, in vitro.</p><p>&nbsp;</p><p>In plasma, a benzoic acid metabolite (M8) of lorlatinib resulting from the oxidative cleavage of the amide and aromatic ether bonds of lorlatinib accounted for 21% of the circulating radioactivity. The oxidative cleavage metabolite, M8, is pharmacologically inactive.</p><p>&nbsp;</p><p><em>Excretion</em></p><p>Following a single oral 100 mg dose of radiolabeled lorlatinib, 48% of the radioactivity was recovered in urine (&lt;1% as unchanged) and 41% in feces (about 9% as unchanged).</p><p>&nbsp;</p><p><u>Specific Populations</u></p><p><u>&nbsp;</u></p><p>No clinically significant differences in lorlatinib pharmacokinetics were observed based on age (19 to 85 years), sex, race/ethnicity, body weight, mild to moderate renal impairment (CLcr 30 to 89 mL/min, estimated by Cockcroft‑Gault), mild hepatic impairment (total bilirubin &le; ULN and AST &gt; ULN or total bilirubin &gt; 1 to 1.5 &times; ULN and any AST), or metabolizer phenotypes for CYP3A5 and CYP2C19. The effect of moderate to severe hepatic impairment (total bilirubin &ge; 1.5 &times; ULN with any AST) &nbsp;on lorlatinib pharmacokinetics is unknown [see Use in Specific Populations (8.6, 8.7)].</p><p>&nbsp;</p><p><em>Patients with Severe Renal Impairment</em></p><p>Following administration of a single oral 100&nbsp;mg dose of LORBRENA, lorlatinib AUC<sub>inf</sub> increased by 42% in subjects with severe renal impairment (CL<sub>cr</sub> 15 to &lt;30&nbsp;mL/min, estimated by Cockcroft‑Gault) compared to subjects with normal renal function (CL<sub>cr</sub> &ge; 90&nbsp;mL/min, estimated by Cockcroft‑Gault). The pharmacokinetics of lorlatinib have not been studied in patients with end-stage renal disease requiring hemodialysis.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Drug Interaction Studies</u></p><p><u>&nbsp;</u></p><p><em>Clinical Studies </em><em>and Model-Informed Approaches</em></p><p>Effect of strong CYP3A Inducers on Lorlatinib: Rifampin (a strong CYP3A inducer that also activates PXR) 600 mg once daily for 8 days (Days 1 to 8) coadministered with a single oral 100 mg dose of LORBRENA on Day 8. &nbsp;reduced the mean lorlatinib AUCinf by 85% and Cmax by 76%. Grade 2 to 4 increases in ALT or AST occurred within 3 days. Grade 4 ALT or AST elevations occurred in 50%, Grade 3 ALT or AST elevations in 33%, and Grade 2 ALT or AST elevations occurred in 8% of subjects. ALT and AST returned to within normal limits within 7 to 34 days (median 15 days) [see 4.5 Interaction with other medical products and other forms of interactions].</p><p>&nbsp;</p><p><em>Effect of Moderate CYP3A Inducers on Lorlatinib:</em> Modafinil (a moderate CYP3A inducer) decreased AUC<sub>inf</sub> by 23% and decreased C<sub>max</sub> by 22% of a single oral 100 mg dose of LORBRENA [see 4.5 Interaction with other medical products and other forms of interactions].</p><p>&nbsp;</p><p>Effect of Strong CYP3A Inhibitors on Lorlatinib: Itraconazole( a strong CYP3A inhibitor) increased AUCinf by 42% and increased Cmax by 24% of a single oral 100 mg dose of LORBRENA [see 4.5 Interaction with other medical products and other forms of interactions].</p><p>&nbsp;</p><p><em>Effect of Fluconazole on Lorlatinib: </em>Fluconazole is predicted to increase steady‑state AUC<sub>tau</sub> and C<sub>max</sub> of lorlatinib by 59%, and 28%, respectively, following concomitant oral administration of 100 mg of LORBRENA once daily and 200 mg fluconazole once daily <em>[see 4.5 </em><strong>Interaction with other medicinal products and other forms of interaction</strong><em>]</em>.</p><p>&nbsp;</p><p><em>Effect of Moderate CYP3A Inhibitors on Lorlatinib: </em>No clinically significant effect on steady‑state lorlatinib pharmacokinetics is predicted when used concomitantly with verapamil or erythromycin.</p><p>&nbsp;</p><p>&nbsp;</p><p>Effect of Lorlatinib on CYP3A Substrates: LORBRENA 150 mg orally once daily for 15 days decreased AUCinf by 64% and Cmax by 50% of a single oral 2 mg dose of midazolam (a sensitive CYP3A substrate) [see 4.5 Interaction with other medicinal products and other forms of interaction].</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Effect of Lorlatinib on CYP2B6 Substrates: LORBRENA 100 mg orally once daily for 15 days decreased AUCinf by 25% and Cmax by 27% of a single oral 100 mg dose of bupropion (a sensitive CYP2B6 substrate).</p><p>Effect of Lorlatinib on CYP2C9 Substrates: LORBRENA 100 mg orally once daily for 15 days decreased AUCinf by 43% and Cmax by 15% of a single oral 100 mg dose of tolbutamide (a sensitive CYP2C9 substrate).</p><p>&nbsp;</p><p>Effect of Lorlatinib on UGT1A Substrates: LORBRENA 100 mg orally once daily for 15 days decreased AUCinf by 45% and Cmax by 28% of a single oral 100 mg dose of acetaminophen (a UGT1A substrate).</p><p>&nbsp;</p><p>Effect of Lorlatinib on P-gp Substrates: LORBRENA 100 mg orally once daily for 15 days decreased AUCinf by 67% and Cmax by 63% of a single oral 60 mg dose of fexofenadine (a P-gp substrate) <em>[see 4.5 Interaction with other medicinal products and other forms of interaction]</em>.</p><p>&nbsp;</p><p>Effect of Acid-Reducing Agents on Lorlatinib: Concomitant use of a proton pump inhibitor, rabeprazole, did not have a clinically significant effect on lorlatinib pharmacokinetics.</p><p>&nbsp;</p><p><em>In Vitro Studies</em></p><p>&nbsp;</p><p>Effect of Lorlatinib on CYP Enzymes: Lorlatinib is a time-dependent inhibitor as well as an inducer of CYP3A and that it activates PXR, with the net effect in vivo being induction. Lorlatinib induces CYP2B6 and activates the human constitutive androstane receptor (CAR). Lorlatinib and the major circulating metabolite, M8, do not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, orCYP2D6. M8 does not inhibit CYP3A.</p><p>&nbsp;</p><p>M8 does not induce CYP1A2, CYP2B6, or CYP3A.</p><p>&nbsp;</p><p>Effects of Lorlatinib on UDP-glucuronosyltransferase (UGT): Lorlatinib and M8 do not inhibit UGT1A1, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15.</p><p>&nbsp;</p><p>Effect of Lorlatinib on transporter system: Lorlatinibis an inhibitor of P-gp and that it activates PXR (potential to induce P-gp), with the net effect in vivo being induction Lorlatinib inhibits &nbsp;organic cation transporter (OCT)1, organic anion transporter (OAT)3, multidrug and toxin extrusion (MATE)1, and intestinal breast cancer resistance protein (BCRP). Lorlatinib does not inhibit organic anion transporting polypeptide (OATP)1B1, OATP1B3, OAT1, OCT2, MATE2K, or systemic BCRP. M8 does not inhibit P gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2K.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p>&nbsp;</p><p>Carcinogenicity studies have not been conducted with lorlatinib. Lorlatinib was aneugenic in an in vitro assay in human lymphoblastoid TK6 cells and positive for micronuclei formation in vivo in the bone marrow of rats. Lorlatinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay.</p><p>&nbsp;</p><p>Dedicated fertility studies were not conducted with lorlatinib. Findings in male reproductive organs occurred in repeat-dose toxicity studies and included lower testicular, epididymal, and prostate weights; testicular tubular degeneration/atrophy; prostatic atrophy; and/or epididymal inflammation at 15 mg/kg/day and 7&nbsp;mg/kg/day in rats and dogs, respectively (approximately 8 and 2 times, respectively, the human exposure at the recommended dose of 100&nbsp;mg based on AUC). The effects on male reproductive organs were reversible.</p><p>&nbsp;</p><p><strong>Animal Toxicology and/or Pharmacology</strong></p><p>&nbsp;</p><p>Distended abdomen, skin rash, and increased cholesterol and triglycerides occurred in animals. These findings were accompanied by hyperplasia and dilation of the bile ducts in the liver and acinar atrophy of the pancreas in rats at 15 mg/kg/day and in dogs at 2 mg/kg/day (approximately 8 and 0.5 times, respectively, the human exposure at the recommended dose of 100 mg based on AUC). All effects were reversible within the recovery period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LORBRENA is supplied as tablets containing 25&nbsp;mg or 100&nbsp;mg of lorlatinib with the following inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate. The film-coating contains hydroxypropyl methylcellulose (HPMC) 2910/hypromellose, lactose monohydrate, macrogol/polyethylene glycol (PEG)&nbsp;3350, triacetin, titanium dioxide, ferrosoferric oxide/black iron oxide, and iron oxide red.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
Do not use Lorbrena after the expiry date which is stated on the Bottle after EXP:. The expiry date refers to the last day of that month.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Store LORBRENA below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablets:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 mg: 8 mm round, tan, immediate release, film-coated, debossed with &ldquo;Pfizer&rdquo; on one side and &ldquo;25&rdquo; and &ldquo;LLN&rdquo; on the other side</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100 mg: 8.5 mm &times; 17 mm oval, lavender, immediate release, film-coated, debossed with &ldquo;Pfizer&rdquo; on one side and &ldquo;LLN 100&rdquo; on the other side</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Inc.
235 East 42nd Street NY 10017
New York, United Sates of America

 
 
 

MANUFACUTRED BY

Pfizer Manufacturing Deutschland GmbH
Betriebsstatte, Freiburg Mooswaldallee 1
79090 Freiburg, Germany

 

 

PACKED & RELEASED BY

Pfizer Pharmaceuticals LLC
KM 1.9 Road 689, Vega Baja, Puerto Rico (PR) 00693
United States of America


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>